The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Open accessAbstract
OBJECTIVE: Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. METHOD: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1). RESULTS: The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75). The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0). Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score. Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up. CONCLUSIONS: Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an NMDA glutamate receptor antagonist, reduced suicidal ideation within 1–4 hours in major depression(71–75) and bipolar disorder.(76, 77)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [72]
In the citing paper
“Furthermore, ketamine has been reported to also have anti-suicidal and anti-anhedonic actions.14,19,20”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [19]
In the citing paper
“Thirdly, samples were usually small.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Firstly, the suicidal risk was often poorly measured (eg, with one single item of a depression scale).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Recently, ketamine has been shown to have a rapid effect on depressive symptoms and suicidal ideation after a single dose.8 9 10 11”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Secondly, response (usually defined as a 50% score reduction on a scale) was the most common outcome rather than remission (that is, complete absence of suicidal ideas).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“The persistence of the ketamine effect at six weeks of intake is not in line with previous studies10 11 31 and the related meta-analysis,12 but those three studies together analysed only 63 patients.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Altered expression of glutamate receptor N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite glutamate receptors is linked to suicidal behavior (129) and may play a role in the rapid-onset antidepressant and antisuicidal effects of ketamine (130-135).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“The anti–suicidal ideation effect of ketamine is only partly explained by its antidepressant action, and effects on memory and cognition may also play a role (131-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“Intravenous ketamine is a rapidly acting treatment that robustly reduces depressive symptoms and suicidal ideation in hours instead of weeks (130-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Research works printed but not linked: 7
- Prudic J, 1999, J Clin Psychiatry, 60, 104
- 10.1037/0022-006X.47.2.343 · DOI · Paper page
- First MB, 1994, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
- First MB, 1996, Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (Version 2.0)
- McNair DM, 1981, Manual for the Profile of Mood States
- Levine J, 1986, Psychopharmacol Bull, 22, 343
- Muthén LK, 2012, Mplus User’s Guide
Cited by
Sorted by citations
Items 301–400 of 430
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Lie, P. E., Lie, T., Nguyen, M., & Lie, D. Y. C. (2026) · Healthcare · doi:10.3390/healthcare14050634 · Cited by 3
Zaccarelli‐Magalhães, J., Abreu, G. R., Fukushima, A. R., Pantaleon, L. D. P., Ribeiro, B. B., Munhoz, C., Manes, M., de Lima, M. A., Miglioli, J., Flório, J. C., et al. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114799 · Cited by 3
Shan, Z., Can, A., Mohamed, A. Z., Dutton, M., Hermens, D. F., Calhoun, V. D., Williams, L. M., Bennett, M. R., & Lagopoulos, J. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01831-x · Cited by 3
Zhou, X., Fuyi, S., Ti, Y., Li, S., Kang, Z., Wang, Y., & Shengqiong, D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241268884 · Cited by 3
Scott, E., Thekkuden, D. T., Kerr, K., & Meurk, C. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251374472 · Cited by 3
Wang, Y. (2024) · American Journal of Translational Research · doi:10.62347/rrzf5229 · Cited by 3
de la Salle, S., Phillips, J. L., Blier, P., & Knott, V. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319456 · Cited by 3
Updates on Preclinical and Translational Neuroscience of Mood Disorders
Mischel, N., Kritzer, M. D., Patkar, A. A., Masand, P. S., & Szabo, S. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001132 · Cited by 3
Regen, F., & Benkert, O. (2018) · Springer eBooks · doi:10.1007/978-3-662-57334-1_1 · Cited by 4
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_4 · Cited by 3
Suizidpräventive Effekte von Ketamin und Esketamin
Plöderl, M., Hengartner, M. P., & Volkmann, C. (2022) · Nervenheilkunde · doi:10.1055/a-1761-3192 · Cited by 2
Acute Suicidal Ideation in the Context of Esketamine Maintenance Therapy
Bell, F. (2023) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2023.180305 · Cited by 2
Assessing suicide risk in chronic pain management: a narrative review across drug classes
Brezić, N., Gligorevic, S., Candido, K. D., & Knežević, N. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2391999 · Cited by 2
Chen, M.-H., Su, T., Lin, W.-C., Li, C., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., & Tu, P. (2024) · Pharmacopsychiatry · doi:10.1055/a-2499-7207 · Cited by 2
Zhang, S., Afshar, H. T., Colvonen, P. J., Nokes, B. T., Compton, J. N., Mishra, J., Bismark, A. W., Ramanathan, D., & Koloski, M. F. (2025) · CNS Drugs · doi:10.1007/s40263-025-01180-w · Cited by 2
Yadav, E., Tekkalaki, B. V., Gadadavar, K. P., Yadawad, V. S., Chate, S. S., Patil, S., & Koparde, V. (2025) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251334446 · Cited by 2
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight
Kutz, C. J., Mistry, A. M., & Dukes, C. H. (2025) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6619.2025 · Cited by 2
Wallach, J. V., Cameron, S., Dybek, M. B., Stanley, B., Orme, C., Riad, N., Kavanagh, P. V., Brandt, S. D., Knapp, A., Gamrat, J. M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02700 · Cited by 2
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 2
Self-citationEvaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review
Vasudeva, S., Lovell, G. F. M., Wong, S., Le, G. H., Orsini, D. K., Luch, S. D. D., McIntyre, R. S., & Rosenblat, J. D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453814 · Cited by 2
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 2
Sajid, S., Lawrence, R. E., Galfalvy, H., Keilp, J. G., Moitra, V. K., Mann, J. J., & Grunebaum, M. F. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100690 · Cited by 2
Self-citationSeyedoshohadaei, S. A., Darehbagh, R. R., Gholami, F., Nouri, E., Babahajiani, M., Kohnepoushi, P., Moradi, Y., & Azizkhani, L. (2024) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00428-3 · Cited by 2
Hood, A., Corlett, C. E., Alldredge, C. T., & Elkins, G. R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00383 · Cited by 3
Zheng, F., Hu, Z., Chen, H., Cheng, J., Hou, Q., Zheng, J., Gong, X., Ji, J., Zayniddin, N., Abduahadi, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117538 · Cited by 2
Ladha, K. S., Lee, J., Mattina, G. F., Pazmino‐Canizares, J., Wijeysundera, D. N., Nezhad, F. G., Tassone, V. K., Adamsahib, F., Lou, W. Y. W., Kennedy, S. H., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10823 · Cited by 2
Ketamine as a Rapid Antidepressant
Cusin, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_10 · Cited by 2
Back to the Future: Ketamine and Nitrous Oxide in Major Refractory Depression
(2017) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2017.09.00345 · Cited by 2
Treatment-resistant psychotic depression
Koretski, J. A., & Rothschild, A. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00024-4 · Cited by 2
Overview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Barzkar, M., Alavi, K., Malakouti, K., Khajeh-Azad, M.-A., Barzkar, F., Jalali Nadoushan, A. H., & Lahiji, M. N. (2025) · BMC Research Notes · doi:10.1186/s13104-024-07029-7 · Cited by 1
Способы и средства медикаментозной профилактики суицидов
Kozlov, V. A., Голенков, А. В., & Евгеньевна, Б. И. (2023) · Суицидология · doi:10.32878/suiciderus.23-14-02(51)-36-58 · Cited by 1
Application of Anesthetic Agents in Depression
Vutskits, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93273-8.00026-2 · Cited by 1
Greiner, C., Chen, C., Sabé, M., & Prada, P. (2024) · Cogent Psychology · doi:10.1080/23311908.2024.2411868 · Cited by 1
Uyar, B., & Güneş, M. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae142 · Cited by 1
Esketamine-Induced Dissociation: A Case Report
Scarcella, J., MacDaniels, J. S., Coffin, L., & Schwartz, T. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424283 · Cited by 1
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1
Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70044 · Cited by 1
Psychedelics as a potential treatment for borderline personality disorder: A narrative review
Artna, E., Sandhu, G., Chisamore, N., Lipsitz, O., Kaczmarek, E. S., Johnson, D. E., Rosenblat, J. D., & Sediqzadah, S. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117152 · Cited by 1
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v33i3.13224 · Cited by 1
Suicide in cancer patients undergoing palliative care: A report of two cases
Huertas, L. A., Rodríguez-Mayoral, O., García-Salamanca, M. F., Monreal-Carrillo, E. A., & Allende‐Pérez, S. (2022) · Salud Mental · doi:10.17711/sm.0185-3325.2022.012 · Cited by 1
New Progress in the Treatment of Refractory Depression with Esticketamine
孙, 诗. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125592 · Cited by 1
Capa, L. S., Tronco, G. S., Reinert, V. N., Klockner, J., Mariussi, P. M., & Fighera, M. R. (2023) · International Journal of Health Science · doi:10.22533/at.ed.1593252303041 · Cited by 1
Use of ketamine for reversing acute depression in a critically ill pretransplant patient
Shapiro, A. B., Chauhan, M., Martin, A. K., & Sanghavi, D. K. (2023) · JHLT Open · doi:10.1016/j.jhlto.2023.100005 · Cited by 1
Parreira, G. M., de Oliveira, A. C. P., Guarnieri, L. D. O., & Vieira, R. P. (2024) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815179842124120007 · Cited by 1
Schüle, C., Koller, G., & Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2309-6457 · Cited by 1
Case report: Dezocine’s rapid and sustained antidepressant effects
Wang, H., Lyu, N., & Zhao, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1411119 · Cited by 1
Nakatsuka, D., Suwa, T., Deguchi, Y., Fujita, Y., Tashima, R., Ohnami, S., Kawashima, H., Oishi, N., Ogawa, K., Yamakawa, H., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03284-9 · Cited by 1
Zhang, L., & Swaab, D. F. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19102-2.00018-1 · Cited by 1
Bajwa, A. A., Ali, S., Khan, S. A., Saleem, N., & Nazir, T. B. (2023) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v73i1.8818 · Cited by 1
Cohen, J., Reichelt, A. C., Zamyadi, R., Roberts, G., Hardy, S., Fernandes, B., Rhind, S. G., Lewis, E. C., Bhat, V., Palner, M., et al. (2025) · medRxiv · doi:10.1101/2025.02.25.25322463 · Cited by 1
Plöderl, M., Cooper, R. E., Walker, T., Shah, V., Horowitz, M. A., Volkmann, C., & Moncrieff, J. (2025) · medRxiv · doi:10.1101/2025.08.19.25333796 · Cited by 1
Courtet, P., Nobile, B., & Olié, É. (2020) · HAL · doi:10.1051/medsci/2020229
Модуляторы глутаматных NMDA-рецепторов — перспективная группа антидепрессантов
Кудряшов, Н. В., Устинова, М. В., & Калинина, Т. С. (2018) · Экспериментальная и клиническая фармакология · doi:10.30906/0869-2092-2018-81-8-26-36
Ketamine for suicidal ideation treatment: Available evidence remains convincing
Bartoli, F., Crocamo, C., & Carrà, G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.020
Impact, Diagnosis, Phenomenology, and Biology
Coryell, W. H. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_156
Ketamine for Psychiatric Disorders
McShane, R. H. (2019) · Cambridge University Press eBooks · doi:10.1017/9781911623175.017
Curtis, S. D., & Ramnarine, M. R. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.07.013
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson, S. T., & Kitay, B. M. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200113-02
Novel therapeutic drug targets for bipolar disorder
Rosenblat, J. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00037-5
Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model
Zhang, K., & Hashimoto, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00056-6
Prise en charge de la fibromyalgie par des perfusions de kétamine : étude observationnelle
Metayer, B., Cormier, G., Dimet, J., Varin, S., André, V., Caulier, M., Pluchon, Y. M., & Cozic, C. (2021) · Douleur et Analgésie · doi:10.3166/dea-2021-0151
Zaccarelli‐Magalhães, J. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2021.tde-16072021-104019
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Nitrous Oxide: An Old Compound with Emerging Psychotropic Properties
Kamel, L. Y., Quach, D. F., Gott, B. M., & Conway, C. R. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_4
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg014
Glutamate-based preclinical and clinical dysfunction and treatment in bipolar disorder
Decker, A., Bacalzo, B., & Niciu, M. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821398-8.00020-5
Ketamine for suicidal ideation
Giorgi, R. D. (2022) · BMJ · doi:10.1136/bmj.o74
Bylund, D. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.97347-1
Bibliography: Emerging Therapies in Psychiatry
(2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16305
Neuroscience-Informed Treatments
(2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17101
Zhuang, Q.-Q., Zhuang, S., Gong, Y., & Li, S. (2022) · Journal of Shanghai Jiaotong University (Science) · doi:10.1007/s12204-022-2455-0
Tao, Y., Xu, H., & Huang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.013
Potencial terapêutico da cetamina em transtornos depressivos
Mendes, L. F. D. S., Bezerra, C. D. S., Piauilino, B. C. N., de Sousa, L. L., Leal, A. K. M. P., Moura, P. R. D. S. E. S., da Silva, L. S. A., Noronha, M. Y. D. C., & Menezes, A. G. V. A. (2023) · Research Society and Development · doi:10.33448/rsd-v12i2.40153
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Moussiopoulou, J., Slapakova, L., Kirsch, B., Mei, E. W. Y., & Schüle, C. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100110
Suicide Preventive Interventions and Knowledge
(2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021002
Schettino, M., Parrillo, C., Gazzellini, S., Cairone, L., Baldassari, G., Thayer, J. F., Giove, F., Napolitano, A., & Ottaviani, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3015876/v1
Zaccarelli‐Magalhães, J., Abreu, G. R., Fukushima, A. R., Pantaleon, L. D. P., Ribeiro, B. B., Munhoz, C., Manes, M., de Lima, M. A., Miglioli, J., Flório, J. C., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4505838
de Melo, I. R., Oliveira, A. L. F., Lessa, V. J. C., Cavalcanti, I. D. F., Alves, M. F. T., & Lima, F. G. P. S. D. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n4-333
Saúde mental e bem-estar Vol. 1
(2023) · Seven Editora eBooks · doi:10.56238/saudementalebemest
Utilização de cetaminas em pacientes refratários ao tratamento convencional do TDM
Furtado, M. D. O., & Coelho, R. C. R. A. B. (2023) · Research Society and Development · doi:10.33448/rsd-v12i11.43894
Improvement of Mental Health Symptoms in Response to Ketamine Therapy in Medicaid-Eligible Patients
Bonnett, C. J., Bonder, J. H., Jain, R., Stabbert, A., & Sayre, C. (2024) · Journal of Psychiatry and Mental Health · doi:10.16966/2474-7769.151
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
Ketamine, Dissociation, and Depression: What Is “Special” About Ketamine? (Revisited)
Rizk, M., & Murrough, J. W. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae024
Are ketamine and its enantiomers the answer to treatment-refractory depression?
Belge, J.-B., Scantamburlo, G., & Constant, E. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2373302
Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
Szafrańska, W., Poborowska, D., Gańko, T., Kahan, W., Bąk, E., Fordymacki, J., Wojaczek, M., Polańska, K., & Najjar, O. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.53331
CETAMINA COMO INTERVENÇÃO TERAPÊUTICA NA DEPRESSÃO PSICÓTICA E DEPRESSÃO REFRATÁRIA A TRATAMENTO
dos Santos, P. P., Silvério, A. P., Ribeiro, B. C., Rodrigues, L. C., & Nunes, Y. T. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i8.5624
Fong, T. H., Li, T., Ma, X., Cai, X., & Zhou, Q. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.20.619255
Kopeček, M., Andrashko, V., Knytl, P., & Horáček, J. (2024) · Psychiatrie pro praxi · doi:10.36290/psy.2024.024
Chapter 16. Preventative and Emerging Pharmacological and Nonpharmacological Treatments
Dickstein, D. P., & Croarkin, P. E. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379200.lg16
Chapter 30. Understanding and Preventing Suicide
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg30
Borderline personality disorder: identification, comorbidity, and emerging treatment opportunities
Zobin, М. L. (2025) · Neurology Bulletin · doi:10.17816/nb677346
Zaremba, M., & Kleczkowska, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_17
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 3
Intravenous ketamine for suicide ideation in borderline personality and depression
Bachir, Y., Kassab, R., Hallal, C., Cordahi, C. C., Hachem, C. E., & Khalil, R. B. (2025) · L Encéphale · doi:10.1016/j.encep.2025.04.008
Schettino, M., Parrillo, C., Gazzellini, S., Cairone, L., Baldassari, G., Thayer, J. F., Giove, F., Napolitano, A., & Ottaviani, C. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02992-2
Street ketamine use and differential risk of suicidality among adults in Taiwan
Kuo, Y.-C., Wang, S., & Chen, C. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01308-7
Metadata
- Authors
- Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the Molecular Imaging and Neuropathology Division, Department of Psychiatry, and the Department of Anesthesiology, Columbia University Medical Center and New York State Psychiatric Institute, New York.
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2018-04-01
- Volume
- 175
- Issue
- 4
- Pages
- 327-335
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5880701
- OpenAlex
- W2771797851
- Cited by
- 431
- References
- 47
- Citations by year
- 2026: 31 · 2025: 45 · 2024: 52 · 2023: 57 · 2022: 62 · 2021: 54 · 2020: 55 · 2019: 43 · 2018: 31
- FWCI
- 24.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH096784)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, midazolam, suicidal ideation, major depressive disorder, rapid-acting antidepressants, adjunctive pharmacotherapy, suicide risk reduction, antidepressant effects, mediation analysis
- MeSH terms
- Behavior Rating Scale, Suicide Prevention, Adult, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Suicide, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
